Morning SARS-CoV-2 Testing Yields Better Detection of Infection Due to Higher Viral Loads in Saliva and Nasal Swabs upon Waking

Alexander Viloria Winnett,a Michael K. Porter,a Anna E. Romano,a Emily S. Savela,a Reid Akana,a Natasha Shelby,a Jessica A. Reyes,a Noah W. Schlenker,a Matthew M. Cooper,a Alyssa M. Carter,a Jenny Ji,a Jacob T. Barlow,a Colten Tognazzini,b Matthew Feaster,b Ying-Ying Goh,b Rustem F. Ismagilov

aCalifornia Institute of Technology, Pasadena, California, USA
bCity of Pasadena Public Health Department, Pasadena, California, USA

Alexander Viloria Winnett and Michael K. Porter contributed equally to this report. Author order was determined by extent of contributions.

ABSTRACT Optimizing specimen collection methods to achieve the most reliable SARS-CoV-2 detection for a given diagnostic sensitivity would improve testing and minimize COVID-19 outbreaks. From September 2020 to April 2021, we performed a household-transmission study in which participants self-collected specimens every morning and evening throughout acute SARS-CoV-2 infection. Seventy mildly symptomatic participants collected saliva, and of those, 29 also collected nasal swab specimens. Viral load was quantified in 1,194 saliva and 661 nasal swab specimens using a high-analytical-sensitivity reverse transcription-quantitative PCR (RT-qPCR) assay. Viral loads in both saliva and nasal swab specimens were significantly higher in morning-collected specimens than in evening-collected specimens after symptom onset. This aspect of the biology of SARS-CoV-2 infection has implications for diagnostic testing. We infer that morning collection would have resulted in significantly improved detection and that this advantage would be most pronounced for tests with low to moderate analytical sensitivity. Collecting specimens for COVID-19 testing in the morning offers a simple and low-cost improvement to clinical diagnostic sensitivity of low- to moderate-analytical-sensitivity tests.

IMPORTANCE Our findings suggest that collecting saliva and nasal swab specimens in the morning immediately after waking yields higher SARS-CoV-2 viral loads than collection later in the day. The higher viral loads from morning specimen collection are predicted to significantly improve detection of SARS-CoV-2 in symptomatic individuals, particularly when using moderate- to low-analytical-sensitivity COVID-19 diagnostic tests, such as rapid antigen tests.

KEYWORDS COVID-19, pandemic, diagnostic, screening, analytical sensitivity, outpatient, ambulatory, circadian rhythm, specimen collection, viral load, sample collection

Although vaccination has substantially reduced hospitalizations and death from COVID-19, limited vaccine uptake and availability and the potential for breakthrough infections (particularly with novel viral variants) support the continued necessity for diagnostic testing and subsequent isolation of infected individuals (1, 2). Optimizing how diagnostics are used can enhance our ability to combat the COVID-19 pandemic.

Nasopharyngeal swab, anterior nares swab, midturbinate swab, oropharyngeal swab, buccal swab, gingival crevicular fluid, sputum, tracheal aspirate, and saliva have all been utilized and compared as diagnostic specimens for the detection of SARS-CoV-2 infection. Work done by many groups (3–5), including ours (6), has suggested that SARS-CoV-2 is detectable, albeit at low viral loads, in saliva before anterior nares nasal swab specimens.

Editor Tulip A. Jhaveri, University of Mississippi Medical Center
Copyright © 2022 Viloria Winnett et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.
Address correspondence to Rustem F. Ismagilov, rustem.admin@caltech.edu.
The authors declare a conflict of interest. R.F.I. is a co-founder, consultant, and a director and has stock ownership of Talis Biomedical Corp.
Received 27 September 2022
Accepted 3 October 2022
Published 26 October 2022
However, conflicting results have been reported in head-to-head comparisons of saliva to other specimen types in cross-sectional studies. Lack of clarity on which specimen type is most reliable for SARS-CoV-2 detection is likely due to the dynamic nature of viral loads in different specimen types through the course of an infection (3, 6–11) and the differences in analytical sensitivity of diagnostic assays used in the comparisons. Currently available SARS-CoV-2 diagnostics span a wide (6 orders of magnitude) range of analytical sensitivities, from the reverse transcription-PCR (RT-PCR) PerkinElmer new coronavirus nucleic acid detection kit (limit of detection [LOD] of 180 nucleic acid amplification test detectable units [NDU]/mL) (12) to the Coris BioConcept rapid antigen lateral flow assay COVID-19 Ag Respi-Strip (LOD of \(10^4\) to \(10^6\) copies/mL of specimen) (13). Tests with relatively moderate analytical sensitivity (LOD of \(10^4\) to \(10^5\) copies/mL of specimen) or low analytical sensitivity (LOD of \(10^5\) to \(10^8\) copies/mL of specimen) are being increasingly used, particularly for at-home and rapid screening testing and in areas of the world with limited laboratory capacity (14–16).

How specimens are collected can also affect the detectability of SARS-CoV-2 in a specimen. Because SARS-CoV-2, like other pathogens, may exhibit circadian rhythms to replication kinetics (17, 18), we hypothesized that collection time may impact SARS-CoV-2 viral load in respiratory specimens and therefore detectability of infection. Simple, low-cost changes to specimen collection protocols that significantly improve the clinical sensitivity of COVID-19 diagnostics offer an immediately actionable opportunity to improve existing diagnostics, which would be particularly valuable in settings that rely on tests with low analytical sensitivity.

We conducted a COVID-19 household transmission study (9, 19) where participants prospectively self-collected saliva and nasal swab specimens twice per day (in the morning and in the evening). From mildly symptomatic participants, we compared SARS-CoV-2 viral loads in morning- and evening-collected specimens to determine if the time of day affected viral load, and if this could be leveraged to improve detection of SARS-CoV-2 infection.

**RESULTS**

**Timing of morning and evening specimen collection.** Viral load was quantified in 1,194 saliva specimens from 70 individuals and 661 nasal swab specimens from 29 individuals (Fig. 1). The distribution of collection times was roughly bimodal. Although each participant’s specimen collection time varied slightly throughout enrollment, nearly all (92%) participants had an average morning specimen collection time between 7 a.m. and 10 a.m. Evening collection time was more variable, but most participants (74%) had an average specimen collection time between 8 p.m. and 11 p.m. These patterns were used to delineate the morning and evening periods in the study: we defined sampling upon waking (4 a.m. to 12 p.m.) as morning...
Saliva and nasal swab specimens exhibit higher viral loads in morning than evening collection across the course of acute, symptomatic illness. Saliva and nasal swab viral load profiles from most individuals (Fig. S2 and S3) revealed a pattern of higher viral loads in specimens collected in the morning than in those collected in the evening. In specimens from some individuals (e.g., Fig. S2A and S3E), fluctuations in both SARS-CoV-2 and human RNase P markers were observed, whereas in others RNase P remained stable and SARS-CoV-2 viral load appeared to be independent of the host marker (e.g., Fig. S2AH and S3N).

Although direct comparison between all positive morning or evening specimens demonstrates greater target abundance for both SARS-CoV-2 N1 (Fig. S4A and C) and human RNase P (Fig. S4B and D), this comparison would be skewed by participants who contributed more specimens and biased by sampling at different stages of the infection. To minimize these potential biases, the time of each specimen collection was aligned relative to the date of symptom onset for that participant before plotting both individual viral load data-points (Fig. S2 and S3) and the average of log-transformed viral load values (Fig. 1A and B) for all saliva and nasal swab specimens in 12 hour time bins.

The averaged salivary viral load during each collection time point visually suggests higher viral loads in specimens collected in the morning than in the evening during both the presymptomatic and symptomatic phases of infection. This pattern was less apparent in the averaged nasal swab viral loads but can be seen when comparing the N1 threshold cycle (C_T) values between successive time points by calculating differences in C_T (Fig. 2A and B). Only reverse transcription-quantitative PCR (RT-qPCR) C_T values for pairs of successively collected morning-to-evening or evening-to-morning specimen were used to calculate the C_T difference; negative or indeterminate specimens were included only if directly followed by a positive specimen collected in the presymptomatic phase of infection. A negative difference in C_T values indicates that viral load was increasing relative to the previous measurement, whereas a positive difference indicates that viral load was decreasing relative to the previous measurement. Starting from symptom onset (day 0), saliva specimens collected in the morning typically exhibited a negative difference in C_T values relative to their preceding evening specimens, whereas evening specimens consistently had a positive difference in C_T values relative to their preceding morning specimens. This indicates that throughout the course of symptomatic infection, morning specimens typically result in relatively lower C_T values (higher viral loads) than evening specimens.

To further illustrate the pattern observed in viral loads and changes in C_T values, specimens were binned by infection stage: prior to symptom onset and in 4-day intervals relative to symptom onset. The 4-day interval was selected to capture reasonable resolution for infection stage while also providing sufficient measurements to observe potential differences. Significantly higher morning viral loads were not observed prior to symptom onset in either specimen type in the limited number of specimens collected during this period. However, significantly higher viral loads (P < 0.05, Wilcoxon matched-pair signed-rank test) were observed in saliva specimens collected in the morning for the first 16 days of symptomatic infection (Fig. 2C). Differences in C_T values were also significantly lower (P < 0.05, Wilcoxon matched-pair signed-rank test) in morning nasal swab specimens from day 4 to day 16 of symptomatic infection (Fig. 2D). Of note, nasal swab viral load appears to increase more quickly to peak than does salivary viral load (Fig. 1A and B), and nasal swabs also achieve higher peak viral loads (Fig. S4C) than does saliva (Fig. S4A); the high rate of increase in viral load in nasal swabs likely obscures subtle daily fluctuations that are more apparent in saliva, where viral load rises more gradually (19). Nasal swabs appear to also be subject to more sampling variability (Fig. S3 and S4D) than saliva (Fig. S2 and S4B), evidenced by RNase P control marker C_T values.

Saliva and nasal swab viral loads in the range of moderate- and low-sensitivity tests underscore utility of morning sampling. The observed higher viral loads in specimens collected in the morning upon waking than in those collected later in the day led us to hypothesize that sampling in the morning could detect significantly more infected individuals than sampling in the evening. Because viral loads rise and decline throughout the course
of the infection (Fig. 1), we assessed this hypothesis during discrete 4-day time bins following symptom onset. The presymptomatic period was not assessed, as few specimens from this period were available for analysis. Additionally, because COVID-19 diagnostics have analytical sensitivities that span several orders of magnitude, we tested this hypothesis for assays with limits of detection (LODs) of $10^3$, $10^4$, $10^5$, $10^6$, $10^7$ copies/mL; quantitative viral loads measured in each specimen were used to predict whether each specimen would reliably yield a positive result when tested by an assay of each LOD. For each time bin and each LOD, we generated two-by-two matrices to assess the detectability of morning or evening sampling within pairs of sequentially collected morning-to-evening (Fig. 3) specimens. Each time bin and LOD that did not contain at least 10 positive samples from saliva or nasal swab were excluded from this analysis.

For saliva specimens, the advantage of morning sampling was statistically significant in all but two comparisons (Fig. 3A); the two comparisons for which a nonsignificant advantage was observed occurred in the first 4 days of infection, at the LODs of the lowest- and highest-analytical-sensitivity assays (LODs of $10^6$ and $10^3$ copies/mL, respectively). As LOD increases, fewer pairs are predicted to have detectable virus in either the morning or evening specimen; for this reason, confidence intervals widen as the LOD increases, which results in decreased power to detect significant differences in detection by assays with higher LODs. Additionally, assays with lower LODs are able to reliably detect lower viral concentrations, decreasing the impact of fluctuations in viral load from morning to evening sampling on detection.
Morning sampling with nasal swab specimens also exhibited an advantage over evening sampling after 4 days from symptom onset, for all LODs (Fig. 3B). In the first 4 days of infection, a nonsignificant advantage of evening over morning sampling was observed; in this phase of the infection, viral loads in nasal swab specimens typically rise rapidly from undetectable to high (Fig. 1). Therefore, during this rapid rise, the specimen collected later within a pair of successively collected specimens would improve detection; indeed, when morning-to-evening pairs were assessed (Fig. 3), the later (evening) time point had improved detection but when evening-to-morning pairs were assessed (Fig. S5), the later (morning) time point resulted in improved detection.

Morning sampling with nasal swab specimens also exhibited an advantage over evening sampling after 4 days from symptom onset, for all LODs (Fig. 3B). In the first 4 days of infection, a nonsignificant advantage of evening over morning sampling was observed; in this phase of the infection, viral loads in nasal swab specimens typically rise rapidly from undetectable to high (Fig. 1). Therefore, during this rapid rise, the specimen collected later within a pair of successively collected specimens would improve detection; indeed, when morning-to-evening pairs were assessed (Fig. 3), the later (evening) time point had improved detection but when evening-to-morning pairs were assessed (Fig. S5), the later (morning) time point resulted in improved detection.

Similarly, when viral loads are declining, one may expect the earlier time point within a pair of successively collected specimens to exhibit improved detection. We assessed whether this effect was responsible for the improved performance of morning sampling over evening sampling...
sampling when pairs of successively collected morning-to-evening specimens were compared by performing an equivalent analysis of pairs of successively collected evening-to-morning specimens (Fig. S5). Even with evening-to-morning pairing, morning sampling exhibited an advantage over evening sampling for all comparisons with saliva and nearly all comparisons with nasal swabs. In the three of 12 comparisons where morning sampling with nasal swabs did not exhibit an advantage, two comparisons had equivalent detection by morning or evening sampling, and in the third comparison evening sampling exhibited only a nonsignificant advantage of less than 2% over morning sampling.

This supports that the advantage of morning sampling over evening sampling for both saliva and nasal swabs was robust to whether the morning specimen is collected prior to or following the evening specimen. These results suggest that collecting saliva or nasal swab specimens for SARS-CoV-2 testing in the morning, immediately after waking, can significantly improve detection of symptomatic, infected individuals.

DISCUSSION

In this study, we quantitatively measured SARS-CoV-2 viral load with high frequency (twice per day) longitudinally through the course of mild COVID-19 infection in saliva for 70 individuals and in nasal swabs for 29 individuals. From these measurements, we identified a pattern of higher viral loads in saliva and nasal swab specimens collected in the morning after waking than in those collected in the evening. Although similar observations have been reported for nasopharyngeal swabs (20, 21), early-morning versus spot oropharyngeal specimens (22), and early-morning saliva versus nasopharyngeal swabs (23) and in wastewater surveillance (24), our study is unique and clinically relevant for three reasons: (i) we measured viral load in specimen types relevant to at-home testing using a high-analytical-sensitivity RT-qPCR assay, which enabled us to infer the performance of diagnostic tests of different analytical sensitivities at each stage of infection; (ii) we collected specimens at high temporal resolution (morning and evening) longitudinally for 2 weeks, starting from early in the course of the infection via prospective sampling of high-risk populations; and (iii) our study provides the largest data set to date that investigates daily patterns in SARS-CoV-2 viral loads, with 1,194 saliva and 661 nasal swab specimens collected longitudinally. From these data, we find compelling evidence that collecting samples for COVID-19 testing in the morning upon waking can significantly improve detection of infected individuals.

The biological and physiological reasons for higher SARS-CoV-2 viral loads in the morning remain unknown but may be due to accumulation of viral material overnight or related to viral replication and immune function. Similar to the improved performance of at-home pregnancy tests with morning urine due to accumulation of human chorionic gonadotropin (25), improved detection of SARS-CoV-2 may be the result of physical accumulation of material (e.g., cells, virions, and nucleic acids) in the upper respiratory tract due to supine positioning (aiding mucociliary clearance) and/or the decreased rate of swallowing at night (26). Higher morning viral loads being due to physical accumulation of nucleic acids is supported by an increased abundance of the constitutive human \( RNase P \) target in saliva and nasal swab specimens collected in the morning (see Fig. S2A and S3A in the supplemental material). Human salivary production decreases overnight (27), suggesting that higher morning viral loads could be due to a concentration of virus when saliva volume is lower. Given that some individuals exhibit this phenomenon independently of human \( RNase P \) target abundance (Fig. S2B and S3B), a circadian rhythm in viral replication may also contribute. Regulation and responsiveness of the immune system have been linked to circadian rhythms (28, 29), shown to affect SARS-CoV-2 infection of monocytes in cell culture (30) and proposed as a modulating factor for COVID-19 severity and management (31). Others have proposed cellular interactions between viral proteins and circadian rhythm-dependent host signals (32) and demonstrated circadian rhythm-dependent entry and proliferation of SARS-CoV-2 in lung epithelial cell types in culture (33). Regardless of mechanism, because higher viral loads are associated with replication-competent culturable virus (34, 35), these findings may also suggest a higher risk of transmission in the morning.

As many individuals remain unvaccinated and new variants emerge, it remains critical to identify infections, promptly isolate infected persons, trace and quarantine contacts, and
initiate early treatment to improve efficacy. Much of the world lacks access to tests with high analytical sensitivity (36–38). Our findings suggest that strategically collecting specimens in the morning immediately after waking up may improve the performance of available low- to moderate-analytical-sensitivity tests. Morning sampling will not raise the performance of tests with low analytical sensitivity to the levels of those with higher analytical sensitivity; however, even marginal improvements in detection have been shown to reduce deaths from COVID-19 (39).

This study is subject to five main limitations. First, we had a limited number of specimens collected prior to the onset of symptoms, limiting our ability to discern a difference in detectability with morning or evening specimens during the presymptomatic phase of infection. Second, this study was performed prior to the dominance of the Delta and Omicron variants of SARS-CoV-2, which may exhibit different viral load kinetics. Host factors, including vaccination status, may also influence viral load kinetics; nearly all individuals in this cohort were unvaccinated. Third, specimens were self-collected without supervision and thus may have had a different quality from those collected by a health care professional. However, many COVID-19 diagnostics in use utilize self-collected specimens, and measurements of the human RNase P gene suggest consistent sampling without failure to collect sufficient material. Fourth, we quantified viral load using RT-qPCR with SARS-CoV-2 N gene target. Many COVID-19 diagnostics utilize N gene targets, and N gene viral loads have been shown to track with other gene targets, suggesting that N gene quantification to viral load conversion would be representative to demonstrate a general phenomenon relevant for diagnostics detecting other viral targets. Fifth, this analysis involves inferring positivity by assays with various analytical sensitivities (LODs), based on the quantitatively measured viral loads. A direct comparison with a specific test is needed to test real-world efficacy.

MATERIALS AND METHODS

**Study design.** Participants were recruited for participation in a COVID-19 household transmission study as previously described (9, 19). Briefly, if at least one member of a household with 2 or more persons had a positive COVID-19 test result within 7 days or was suspected to be positive, all household members aged 6 years and older were eligible to participate. Participants began collecting saliva or saliva and nasal swab specimens on the evening of enrollment and each subsequent morning and evening (as described below). COVID-19-like symptoms were reported via questionnaire with each specimen collection time point.

For participants who were SARS-CoV-2 positive when initially enrolled in the study, symptom onset was defined as the date of first symptoms reported in an enrollment questionnaire. For participants who entered the study SARS-CoV-2 negative but had unrelated symptoms, symptom onset was the first instance of a new COVID-19-like symptom or an increase in symptom severity following their first SARS-CoV-2-positive specimen.

**Specimen collection.** Participants self-collected anterior nares nasal swab and saliva specimens in the Spectrum SDNA-1000 saliva collection kit (Spectrum Solutions LLC, Draper, UT), at home twice per day (after waking up and before going to bed), per manufacturer’s guidelines (although Spectrum devices are not currently authorized for the collection of nasal swab specimens). One participant self-collected both anterior nares nasal swab and saliva specimen in Nest viral transport medium (VTM) (catalog no. NST-NST-202117; Stellar Scientific, Baltimore, MD), and three individuals collected their nasal swab specimens in VTM and their saliva specimens in the Spectrum SDNA-1000 saliva collection kit. Participants were instructed not to ingest anything, smoke, or brush their teeth for at least 30 min prior to collection. For nasal swab collection, participants were asked to gently blow their noses before swabbing (four complete rotations with gentle pressure in each nostril) with sterile flocked swabs. A parent/guardian assisted minors with collection. At collection, participants recorded the date and time and any symptoms experienced in the previous 12 h. Specimens collected between 4 a.m. and 12 p.m. were defined as morning; specimens collected between 3 p.m. and 3 a.m. were defined as evening (see Fig. S1 in the supplemental material).

**Cohort of individuals with SARS-CoV-2 infection.** Between September 2020 and April 2021, 72 participants from 39 households in southern California had acute SARS-CoV-2 infection. Of these, 2 never reported experiencing symptoms and were not included in subsequent analyses where viral loads are aligned with date of symptom onset. Of the 70 symptomatic individuals from 37 households included in the analyses (Table 1), all 70 collected saliva specimens while a subset of 29 individuals collected both saliva and nasal swab specimens every morning and every evening while enrolled, from which we quantified viral loads.

Individuals were enrolled at various stages of infection. Of the 70 infected, symptomatic individuals, 58 were positive for SARS-CoV-2 in the first saliva or saliva and nasal swab specimen collected upon enrollment while 12 were initially negative but became positive while enrolled in the study; of these 12 individuals, 7 were collecting both saliva and nasal swabs, and the viral loads and symptoms of these individuals have been previously reported (6). Of the 58 cases positive on enrollment, 50 (86.2%) were already experiencing mild COVID-19-like symptoms and 8 (13.8%) were presymptomatic. Of the 20 individuals who were either presymptomatic (8) or negative for SARS-CoV-2 (12) on enrollment, COVID-19 symptom onset occurred an average of 1.2 days after the first SARS-CoV-2-positive saliva specimen.
### TABLE 1 Demographic and medical information on participants

| Demographic or medical characteristic | Participants contributing specimen type(s): |  
| --- | --- |  
|  | Saliva (n = 70) | Saliva and nasal swabs (n = 29) |  
|  | No. | % | No. | % |  
| **Sex** |  |  |  |  |  
| Male | 25 | 35.7 | 9 | 31.0 |  
| Female | 45 | 64.3 | 20 | 69.0 |  
| **Age, yr** |  |  |  |  |  
| 6–11 | 6 | 8.6 | 1 | 3.4 |  
| 12–17 | 9 | 12.9 | 4 | 13.8 |  
| 18–24 | 9 | 12.9 | 3 | 10.3 |  
| 25–35 | 17 | 24.3 | 10 | 34.5 |  
| 36–45 | 12 | 17.1 | 3 | 10.3 |  
| 46–55 | 11 | 15.7 | 6 | 20.7 |  
| 56–65 | 5 | 7.1 | 2 | 6.9 |  
| 65+ | 1 | 1.4 | 0 | 0.0 |  
| **Race** |  |  |  |  |  
| Asian/Pacific Islander | 6 | 8.6 | 2 | 6.9 |  
| Black/African American | 2 | 2.9 | 2 | 6.9 |  
| Native American | 0 | 0.0 | 0 | 0.0 |  
| White | 33 | 47.1 | 15 | 51.7 |  
| Multiple races | 4 | 5.7 | 3 | 10.3 |  
| Other/unknown | 25 | 35.7 | 7 | 24.1 |  
| **Ethnicity** |  |  |  |  |  
| Hispanic | 52 | 74.3 | 21 | 72.4 |  
| Non-Hispanic | 17 | 24.3 | 8 | 27.6 |  
| Unknown | 1 | 1.4 | 0 | 0.0 |  
| **Tobacco smoker or vape user history** |  |  |  |  |  
| Current | 5 | 7.1 | 3 | 10.3 |  
| Former | 15 | 21.4 | 9 | 31.0 |  
| Never | 43 | 61.4 | 16 | 55.2 |  
| Unknown | 7 | 10.0 | 1 | 3.4 |  
| **Active medications and supplements** |  |  |  |  |  
| Vitamins/supplements | 47 | 67.1 | 21 | 72.4 |  
| Acetaminophen/NSAIDs | 33 | 47.1 | 13 | 44.8 |  
| Allergy medications/antihistamines | 11 | 15.7 | 3 | 10.3 |  
| Antibiotics/antivirals | 3 | 4.3 | 0 | 0.0 |  
| Steroid drug | 3 | 4.3 | 1 | 3.4 |  
| **Medical comorbidities** |  |  |  |  |  
| Asthma | 6 | 8.6 | 1 | 3.4 |  
| Anxiety or depression | 4 | 5.7 | 2 | 6.9 |  
| Diabetes | 4 | 5.7 | 3 | 10.3 |  
| Obesity | 4 | 5.7 | 2 | 6.9 |  
| Hypertension | 3 | 4.3 | 1 | 3.4 |  
| Immunocompromise | 0 | 0.0 | 0 | 0.0 |  
| **SARS-CoV-2 vaccination status** |  |  |  |  |  
| Partially vaccinated | 1 | 1.4 | 1 | 3.4 |  
| Completed vaccination | 0 | 0.0 | 0 | 0.0 |  
| No vaccines reported | 69 | 98.6 | 28 | 96.6 |  

---

*Demographic and medical information on participants was collected via online questionnaire upon study enrollment. All participants (n = 70) collected saliva; of these 70 individuals, 29 additionally collected nasal swabs.

*Participants were asked to report both sex assigned at birth and current gender identity; all 70 participants in this cohort reported cisgender identities.

*A total of 10 individuals contributing saliva and 2 individuals contributing both saliva and nasal swabs indicated “Other” in the race field and wrote in “Hispanic” or “Latinx/Latina/Latino.”

*NSAIDs, nonsteroidal anti-inflammatory drugs. This number includes 2 individuals (each contributing both saliva and nasal swabs) who indicated they were taking a pain-relieving medication but did not specify the type.

*Complete vaccination was considered a two-dose series of Pfizer-BioNTech (COMIRNATY) or Moderna (Spikevax) COVID-19 vaccines or one dose of Johnson & Johnson’s Janssen COVID-19 vaccine.
ACKNOWLEDGMENTS

We sincerely thank the study participants for making this work possible. We thank Lauriane Quenee, Grace Fisher-Adams, Junie Hildebrandt, Megan Hyashi, RuthAnne Bevier, Chantal D’Apuzzo, Ralph Adolphs, Victor Rivera, Steve Chapman, Gary Waters, Leonard Edwards, Gaylene Ursua, Cynthia Ramos, and Shannon Yamashita for their assistance and advice on study implementation and/or administration. We thank Jessica Leong, Jessica Slagle, Mika Walton, Angel Navano, Daniel Brenner, Ojas Pradhan, Si Hyung Jin, and Mary Arrastia for volunteering their time to help with this study. We thank Angie Cheng, Susan Magdaleno, Christian Kis, Monica Herrera, and Zaina Lemeir for technical discussions regarding saliva extraction and detection. We thank Jennifer Fulcher, Debika Bhattacharya, and Matthew Bidwell Goetz for their ideas on potential study populations and early study design. We thank Omai Garner and David Beenhouwer for providing materials for initial nasal swab validation. We thank Martin Hill, Alma Sanchez, Scott Kim, Debbie Noble, Nina Paddock, Whitney Harrison, Emily Holman, Isaac Turner, Vivek Desai, Luke Wade, Tom Mayell, Stu Miller, Jennifer Howes, and Nari Shin for their support with recruitment. We thank Allison Rhines, Karen Heichman, and Dan Wattendorf for valuable discussions and guidance. We thank David Prober for discussions of circadian rhythms and feedback on the manuscript. Finally, we thank all the case investigators and contact tracers at the Pasadena Public Health Department, the City of Long Beach Department of Health & Human Services, and Caltech Student Wellness Services for their efforts in study recruitment and their work in the pandemic response.

R.F.I. is a cofounder, consultant, and a director and has stock ownership of Talis Biomedical Corp.

This study is based on research funded in part by the Bill & Melinda Gates Foundation (INV-023124). The findings and conclusions contained within are those of the authors and do not necessarily reflect positions or policies of the Bill & Melinda Gates Foundation. This work was also funded by the Ronald and Maxine Linde Center for New Initiatives at the California Institute of Technology and the Jacobs Institute for Molecular Engineering for Medicine at the California Institute of Technology. A.V.W. is supported by a UCLA DGSOM Geffen Fellowship, and M.M.C. is supported by a Caltech Graduate Student Fellowship.
REFERENCES

1. Wadhwa A, Fisher KA, Silver R, Koh M, Arons MM, Miller DA, McIntyre AF, Vuong JT, Kim K, Takamiyi M, Binder AM, Tate JE, Armstrong PA, Black SR, Menella CC, Levin R, Gubser J, Jones B, Welbel SF, Moonan PK, Currin K, Ghinai I, Doshi R, Zawitz CJ. 2021. Identification of presymptomatic and asymptomatic cases using cohort-based testing approaches at a large correctional facility—Chicago, Illinois, USA. May 2020. Clin Infect Dis 72:e128–e135. https://doi.org/10.1093/cid/ciaa1802.

2. Dora AV, Winnett A, Jatt LP, Davar K, Watanabe M, Sohn L, Kern HS, Dora AV, Winnett A, Jatt LP, Davar K, Watanabe M, Sohn L, Kern HS. 2022. Global partnership to make available 120 million affordable, quality COVID-19 rapid tests for low- and middle-income countries. WHO, Geneva. https://www.who.int/news/item/28-09-2020-global-partnership-to-make-available-120-million-affordable-quality-covid-19-rapid-tests-for-low-and-middle-income-countries.

3. Wadhwa A, Fisher KA, Silver R, Koh M, Arons MM, Miller DA, McIntyre AF, Vuong JT, Kim K, Takamiyi M, Binder AM, Tate JE, Armstrong PA, Black SR, Menella CC, Levin R, Gubser J, Jones B, Welbel SF, Moonan PK, Currin K, Ghinai I, Doshi R, Zawitz CJ. 2021. Identification of presymptomatic and asymptomatic cases using cohort-based testing approaches at a large correctional facility—Chicago, Illinois, USA. May 2020. Clin Infect Dis 72:e128–e135. https://doi.org/10.1093/cid/ciaa1802.

4. Wadhwa A, Fisher KA, Silver R, Koh M, Arons MM, Miller DA, McIntyre AF, Vuong JT, Kim K, Takamiyi M, Binder AM, Tate JE, Armstrong PA, Black SR, Menella CC, Levin R, Gubser J, Jones B, Welbel SF, Moonan PK, Currin K, Ghinai I, Doshi R, Zawitz CJ. 2021. Identification of presymptomatic and asymptomatic cases using cohort-based testing approaches at a large correctional facility—Chicago, Illinois, USA. May 2020. Clin Infect Dis 72:e128–e135. https://doi.org/10.1093/cid/ciaa1802.
30. Diallo AB, Gay L, Coiffard B, Leone M, Mezouar S, Mege J-L. 2021. Daytime variation in SARS-CoV-2 infection and cytokine production. Microb Pathog 158:105067. https://doi.org/10.1016/j.micropath.2021.105067.

31. Ray S, Reddy AB. 2020. COVID-19 management in light of the circadian clock. Nat Rev Mol Cell Biol 21:494–495. https://doi.org/10.1038/s41580-020-0275-3.

32. Meira e Cruz M, Miyazawa M, Gozal D. 2020. Putative contributions of circadian clock and sleep in the context of SARS-CoV-2 infection. Eur Respir J 55:2001023. https://doi.org/10.1183/13993003.01023-2020.

33. Zhuang X, Tsukuda S, Wrensch F, Wing PAC, Schilling M, Harris JM, Bornmann H, Morgan SB, Cane JL, Mally L, Thakur N, Conceicao C, Sanghani H, Heydmann L, Bach C, Ashton A, Walsh S, Tan TK, Schimanski L, Huang K-YA, Schuster C, Watashi K, Hinks TSC, Jagannath A, Veale D, Baument TF, McKeating JA. 2021. The circadian clock component BMAL1 regulates SARS-CoV-2 entry and replication in lung epithelial cells. iScience 24:103144. https://doi.org/10.1016/j.isci.2021.103144.

34. Gallichotte EN, Quicke KM, Sexton NR, Fitzmeyer E, Young MC, Janich AJ, Dobos K, Pablonia KL, Gahm G, Carlton EJ, Ebel GD, Ehrhart N. 2020. Longitudinal surveillance for SARS-CoV-2 among staff in six Colorado long-term care facilities: epidemiologic, virologic, and sequence analysis. medRxiv. https://doi.org/10.1101/2020.06.08.20125989.

35. Perera RAPM, Tso E, Tsang OTY, Tsang DNC, Fung K, Leung YYW, Chin AWH, Chu DKW, Cheng SMS, Poon LLM, Chuang WWK, Peiris M. 2020. SARS-CoV-2 virus culture and subgenomic RNA for respiratory specimens from patients with mild coronavirus disease. Emerg Infect Dis 26:2701–2704. https://doi.org/10.3201/eid2611.2023219.

36. Okeke IN, Ihekweazu C. 2021. The importance of molecular diagnostics for infectious diseases in low-resource settings. Nat Rev Microbiol 19:547–548. https://doi.org/10.1038/s41579-021-00598-5.

37. Sander A-L, Yadouleton A, Moreira-Soto A, Tchibozo C, Hounkanrin G, Badou Y, Fischer C, Krause N, Akogbeto P, de Oliveira Filho EF, Dossou A, Brunink S, Drosten C, Aissi MAJ, Harouna Djingarey M, Houmkpatin B, Nagel M, Drexler JF. 2021. An observational laboratory-based assessment of SARS-CoV-2 molecular diagnostics in Benin, Western Africa. mSphere 6:e00979-20. https://doi.org/10.1128/mSphere.00979-20.

38. The Lancet Global Health. 2021. Essential diagnostics: mind the gap. Lancet Glob Health 9:e1474. https://doi.org/10.1016/S2214-109X(21)00467-8.

39. Terriau A, Albertini J, Montassier E, Poirier A, Le Bastard Q. 2021. Estimating the impact of virus testing strategies on the COVID-19 case fatality rate using fixed-effects models. Sci Rep 11:21650. https://doi.org/10.1038/s41598-021-01034-7.

40. Virtanen P, Gommers R, Oliphant TE, Haberland M, Reddy T, Cournapeau D, Burovski E, Peterson P, Weckesser W, Bright J, van der Walt SJ, Brett M, Wilson J, Millman KJ, Mayorov N, Nelson ARJ, Jones E, Kern R, Larson E, Carey JC, Polat I, Feng Y, Moore EW, VanderPlas J, Laxalde D, Perktold J, Cimrman R, Henriksen I, Quintero EA, Harris CR, Archibald AM, Ribeiro AH, Pedregosa F, van Mulbregt P, SciPy 1.0 Contributors. 2020. SciPy 1.0: fundamental algorithms for scientific computing in Python. Nat Methods 17:261–272. https://doi.org/10.1038/s41592-019-0686-2.